247 GSK Annual Report 2016 Strategic report Governance and remuneration Financial statements Investor information Pipeline, products and competition Pharmaceuticals and Vaccines product development pipeline Key In-licence or other alliance relationship with third party S Month of first submission ViiV Healthcare, a global specialist HIV company with BLA Biological Licence Application GSK, Pzer, Inc. and Shionogi Limited as shareholders, MAA Marketing Authorisation Application Europe is responsible for developing and delivering HIV medicines.
NDA New Drug Application US Also being developed for indications in another Phase I Evaluation of clinical pharmacology, usually conducted therapeutic area in volunteers 1 Option-based alliance with Ionis Pharmaceuticals Phase II Determination of dose and initial evaluation of efcacy, 2 Option-based alliance with Adaptimmune Ltd. conducted in a small number of patients 3 Option-based alliance with OncoMed Pharmaceuticals Phase III Large comparative study compound versus placebo 4 Option-based alliance with Telethon and Ospedale and or established treatment in patients to establish San Raffaele clinical benefit and safety 5 Option-based alliance with Valneva MAA and NDA BLA regulatory review milestones shown in the table below are those that have been achieved.
Future ling dates are not included in this list.
Achieved regulatory review milestones Compound Type Indication Phase MAA NDA BLA HIV and Infectious Diseases dolutegravir HIV integrase inhibitor non-nucleoside HIV infections two drug maintenance regimen III rilpivirine reverse transcriptase inhibitor NNRTI dolutegravir HIV integrase inhibitor nucleoside reverse HIV infections III lamivudine transcriptase inhibitor NRTI 3684934 HIV attachment inhibitor HIV infections III cabotegravir HIV integrase inhibitor long-acting parenteral HIV pre-exposure prophylaxis III formulation cabotegravir HIV integrase inhibitor non-nucleoside HIV infections III rilpivirine reverse transcriptase inhibitor NNRTI long-acting parenteral formulations tafenoquine 8-aminoquinoline plasmodium vivax malaria III Relenza i. v. neuraminidase inhibitor i. v. inuenza III gepotidacin type 2 topoisomerase inhibitor bacterial infections II 2140944 danirixin i. v. chemokine C-X-C Motif receptor 2 inuenza II CXCR2 antagonist 2878175 RG101 nonstructural protein 5B NS5B polymerase hepatitis C II inhibitor anti-miR122 antisense oligonucleotide 3342830 antibacterial cephalosporin bacterial infection I 2838232 HIV maturation inhibitor HIV infections I 1 3228836 HBV antisense oligonucleotide hepatitis B I 1 3389404 HBV LICA antisense oligonucleotide hepatitis B I Respiratory uticasone furoate glucocorticoid agonist long-acting beta2 chronic obstructive pulmonary disease COPD Submitted S: Dec16 S: Nov16 vilanterol agonist muscarinic acetylcholine antagonist umeclidinium mepolizumab interleukin 5 IL5 monoclonal antibody COPD III uticasone furoate glucocorticoid agonist long-acting beta2 asthma III vilanterol agonist muscarinic acetylcholine antagonist umeclidinium 961081 muscarinic acetylcholine antagonist, beta2 COPD II agonist MABA 961081 muscarinic acetylcholine antagonist, beta2 COPD II uticasone furoate agonist MABA glucocorticoid agonist danirixin chemokine C-X-C Motif receptor 2 CXCR2 COPD II antagonist oral 2269557 phosphatidylinositol 3-kinase delta PI3K COPD acute and chronic II inhibitor 2586881 recombinant human angiotensin converting acute lung injury II enzyme 2 rhACE2 2862277 tumour necrosis factor receptor-1 TNFR1 acute lung injury II domain antibody mepolizumab interleukin 5 IL5 monoclonal antibody hypereosinophilic syndrome II mepolizumab interleukin 5 IL5 monoclonal antibody nasal polyposis II 2245035 toll-like receptor 7 TLR7 agonist asthma II sirukumab interleukin 6 IL6 human monoclonal antibody s. c. severe asthma II 248 GSK Annual Report 2016 Pipeline, products and competition continued Pharmaceuticals and Vaccines product development pipeline continued Achieved regulatory review milestones Compound Type Indication Phase MAA NDA BLA Respiratory continued 2269557 phosphatidylinositol 3-kinase delta activated PI3K delta syndrome I PI3K inhibitor 3772847 interleukin 33r IL33r monoclonal severe asthma I antibody 2586881 recombinant human angiotensin pulmonary arterial hypertension I converting enzyme 2 rhACE2 3008348 alpha V beta 6 integrin antagonist idiopathic pulmonary brosis I 2269557 phosphatidylinositol 3-kinase bronchietasis I delta PI3K inhibitor Oncology 2 3377794 NY-ESO-1 autologous engineered sarcoma, multiple myeloma, non-small cell lung II TCR-T cells engineered TCR cancer, melanoma and ovarian cancer 3 tarextumab notch 2 3 monoclonal antibody small cell lung cancer II 3174998 OX40 agonist monoclonal antibody solid tumours and haematological malignancies I 2816126 enhancer of zeste homologue2 solid tumours and haematological malignancies I EZH2 inhibitor 525762 BET family bromodomain inhibitor solid tumours and haematological malignancies I 2879552 lysine-specic demethylase 1 LSD1 acute myeloid leukemia and small cell lung cancer I inhibitor 2857916 B-cell maturation antigen antibody multiple myeloma I drug conjugate 3326595 protein arginine methyltransferase 5 cancer I PRMT5 inhibitor 3359609 induced T-cell costimulator ICOS cancer I agonist antibody 1795091 toll-like receptor 4 TLR4 agonist cancer I 2636771 phosphatidylinositol 3-kinase PI3K castration resistant prostate cancer I beta inhibitor Immuno-inammation sirukumab interleukin 6 IL6 human monoclonal rheumatoid arthritis Submitted S: Sep16 S: Sep16 antibody Benlysta B lymphocyte stimulator monoclonal systemic lupus erythematosus Submitted S: Sep16 S: Sep16 antibody s. c. sirukumab interleukin 6 IL6 human monoclonal giant cell arteritis III antibody 3196165 granulocyte macrophage colonyosteoarthritis II stimulating factor monoclonal antibody 3196165 granulocyte macrophage colonyrheumatoid arthritis II stimulating factor monoclonal antibody Benlysta Rituxan B lymphocyte stimulator monoclonal Sjogrens syndrome II antibody s. c. cluster of differentiation 20 CD20 monoclonal antibody i. v. 2982772 receptor-interacting protein 1 RIP1 psoriasis and rheumatoid arthritis II kinase inhibitor 3117391 macrophage targeted histone rheumatoid arthritis II deacetylase inhibitor 2330811 oncostatin M OSM monoclonal systemic sclerosis I antibody 2982772 receptor-interacting protein 1 RIP1 ulcerative colitis I kinase inhibitor 2618960 interleukin 7 IL7 receptor monoclonal Sjogren's syndrome I antibody 2646264 spleen tyrosine kinase Syk inhibitor chronic urticaria I topical 2831781 lymphocyte activation gene 3 LAG3 autoimmune disease I protein monoclonal antibody 3050002 chemokine C-C motif ligand 20 psoriatic arthritis I CCL20 monoclonal antibody 3179106 rearranged during transfection RET inammatory disorders of bowel I kinase inhibitor 249 GSK Annual Report 2016 Strategic report Governance and remuneration Financial statements Investor information Pharmaceuticals and Vaccines product development pipeline continued Achieved regulatory review milestones Compound Type Indication Phase MAA NDA BLA Rare diseases Strimvelis ex-vivo stem cell gene therapy adenosine deaminase severe combined immune Approved A: May16 deficiency ADA-SCID 1 2998728 transthyretin TTR production inhibitor  amyloidosis III 2696274 ex-vivo stem cell gene therapy metachromatic leukodystrophy III 2696275 ex-vivo stem cell gene therapy Wiscott-Aldrich syndrome III mepolizumab interleukin 5 IL5 monoclonal antibody eosinophilic granulomatosis with polyangiitis III 2398852 serum amyloid P component SAP amyloidosis II 2315698 monoclonal antibody SAP depleter CPHPC 4 2696277 ex-vivo stem cell gene therapy beta-thalassemia II 2256098 focal adhesion kinase inhibitor pulmonary arterial hypertension PAH I Vaccines Shingrix recombinant Herpes Zoster prophylaxis Submitted S: Nov16 S: Oct 16 Zoster Vaccine MMR live attenuated measles, mumps, rubella prophylaxis III US N A Ebola recombinant viral vector Ebola haemorrhagic fever prophylaxis II Group B conjugated Group B streptococcus prophylaxis II Streptococcus maternal immunisation S. pneumoniae recombinant conjugated Streptococcus pneumoniae disease prophylaxis II next generation COPD recombinant reduction of the frequency of moderate and severe acute II exacerbations in COPD patients by targetting nontypeable Haemophilus inuenzae and Moraxella catarrhalis Hepatitis C recombinant viral vector hepatitis C virus prophylaxis II Malaria next generation recombinant malaria prophylaxis Plasmodium falciparum II Men ABCWY recombinant conjugated meningococcal A, B, C, W and Y disease prophylaxis II in adolescents Shigella conjugated and outer membrane Shigella diarrhea prophylaxis II Tuberculosis recombinant tuberculosis prophylaxis II RSV recombinant respiratory syncytial virus prophylaxis II maternal immunisation RSV  recombinant respiratory syncytial virus prophylaxis II viral vector HIV recombinant proteins HIV infection prophylaxis II Other pharmaceuticals Metabolic retosiban oxytocin antagonist spontaneous pre-term labour III daprodustat 1278863 prolyl hydroxylase inhibitor oral anaemia associated with chronic renal disease III 2330672 ileal bile acid transport IBAT inhibitor cholestatic pruritus II 2798745 transient receptor potential cation heart failure II channel V4 TRPV4 antagonist 1070806 interleukin 18 IL18 neutralisation mAb delayed graft function after renal transplantation II otelixizumab cluster of differentiation 3 CD3 new onset type 1 diabetes II monoclonal antibody daprodustat 1278863 prolyl hydroxylase inhibitor topical wound healing I 3008356 diglyceride acyltransferase DGAT 1 nonalcoholic steatohepatitis I inhibitor 2881078 selective androgen receptor modulator muscle wasting I oxytocin inhaled oxytocin postpartum hemorrhage I Dermatology mepolizumab interleukin 5 IL5 monoclonal antibody atopic dermatitis II 2894512 non-steroidal anti-inammatory topical atopic dermatitis II 2894512 non-steroidal anti-inammatory topical psoriasis II 2981278 ROR gamma inverse agonist topical psoriasis II Neurosciences 1 IONIS-GSK4-L ocular target LICA antisense geographic atrophy age-related macular disease I oligonucleotide Brand names appearing in italics are trademarks either owned by and or licensed to GlaxoSmithKline or associated companies
